Latest Boardroom Shifts News

BSA Limited reported an 84% plunge in revenue for the half-year ending December 2025, driven by lost contracts and reduced volumes, yet managed a $6.3 million profit amid restructuring and cost controls. Significant board changes signal a strategic reset as the company navigates uncertain waters.

Murray Cod Australia has appointed Steven Chaur as its new Managing Director and CEO, aiming to accelerate revenue growth and operational efficiency from April 2026. The move signals a strategic push to deepen domestic channels and expand the luxury fish brand’s market presence.

Li-S Energy narrows its loss to $1.21 million in H1 2026, propelled by a $7.8 million ARENA grant and key manufacturing milestones including Australia’s first lithium metal foil production line. Strategic defence and aerospace partnerships bolster its commercialisation drive.

Terragen Holdings reports a 23% reduction in half-year net loss amid strategic shifts and completes a $7 million equity raise to accelerate global commercialisation of its biological agricultural products.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

Adrad Holdings reported a modest revenue rise and a dip in statutory profit for the half-year ending December 2025, while its Heat Transfer Solutions segment showed robust growth. The company declared a fully franked interim dividend, reflecting confidence amid ongoing restructuring.

Enero Group’s half-year results reveal a 6.3% revenue decline but a striking 119% surge in adjusted profit, alongside strategic leadership changes and a steady dividend.

IPH Limited reported a solid half-year performance with revenue up 6.5% to $363.9 million and net profit rising 10.5% to $41.2 million, driven by strong gains in Canada and Asia despite a decline in Australia and New Zealand.

Ventia Services Group Limited reported a 23.6% increase in profit after tax for FY25 to $272.2 million, alongside record contract wins and a strong sustainability agenda. The company declared a 12.54 cents per share final dividend, underscoring its commitment to shareholder returns and operational excellence.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

IDT Australia reports a robust 20.3% increase in core revenue and a dramatic narrowing of EBITDA losses, signalling early success from its strategic realignment under new leadership.

TechnologyOne has upgraded its FY26 profit and recurring revenue growth forecasts, citing strong confidence in AI-enhanced SaaS+ products and a robust customer pipeline across key markets.